Pixium Vision has received approval to begin human trials of its second generation epi-retinal implant, Iris 150. Application for CE mark was filed based on data from the first-generation implant. The first-generation implant has proved to be well tolerated and enables vision restoration to the object recognition level. Iris 150 theoretically should allow better vision. Using a risk-adjusted NPV model, we value the company at €10.27, adjusted down by €0.24 to reflect updated cash of
08 Jan 2016
Introducing the second-generation implant
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Introducing the second-generation implant
Pixium Vision has received approval to begin human trials of its second generation epi-retinal implant, Iris 150. Application for CE mark was filed based on data from the first-generation implant. The first-generation implant has proved to be well tolerated and enables vision restoration to the object recognition level. Iris 150 theoretically should allow better vision. Using a risk-adjusted NPV model, we value the company at €10.27, adjusted down by €0.24 to reflect updated cash of